Alectinib combined with bevacizumab (angiogenesis agent targeting vascular endothelial growth factor–VEGF) is being tested in patients with ALK-rearranged NSCLC with at least one target lesion in CNS (NCT02521051) and combinations of ceritinib with either LEE011 (CDK4/6 inhibitor) or everolimus (mTOR inhibitor) are in early-phase testing in NSCLC (NCT02292550 and NCT02321501, respectively). The gene discussed is ALK; the disease is non-small cell lung carcinoma.